- Home
- ENVA vs APGE Comparison
ENVA vs APGE Comparison
Compare ENVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVA
- APGE
- Stock Information
- Founded
- ENVA 2011
- APGE 2022
- Country
- ENVA United States
- APGE United States
- Employees
- ENVA N/A
- APGE 91
- Industry
- ENVA Finance: Consumer Services
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENVA Finance
- APGE Health Care
- Exchange
- ENVA Nasdaq
- APGE Nasdaq
- Market Cap
- ENVA 2.6B
- APGE 2.3B
- IPO Year
- ENVA N/A
- APGE 2023
- Fundamental
- Price
- ENVA $111.71
- APGE $40.59
- Analyst Decision
- ENVA Buy
- APGE Strong Buy
- Analyst Count
- ENVA 7
- APGE 5
- Target Price
- ENVA $88.00
- APGE $83.50
- AVG Volume (30 Days)
- ENVA 183.9K
- APGE 465.4K
- Earning Date
- ENVA 02-04-2025
- APGE 03-04-2025
- Dividend Yield
- ENVA N/A
- APGE N/A
- EPS Growth
- ENVA 5.61
- APGE N/A
- EPS
- ENVA 6.23
- APGE N/A
- Revenue
- ENVA $1,170,788,000.00
- APGE N/A
- Revenue This Year
- ENVA N/A
- APGE N/A
- Revenue Next Year
- ENVA $17.19
- APGE N/A
- P/E Ratio
- ENVA $17.85
- APGE N/A
- Revenue Growth
- ENVA 14.80
- APGE N/A
- 52 Week Low
- ENVA $53.17
- APGE $32.78
- 52 Week High
- ENVA $113.08
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- ENVA 68.60
- APGE 41.41
- Support Level
- ENVA $93.99
- APGE $37.60
- Resistance Level
- ENVA $113.08
- APGE $40.75
- Average True Range (ATR)
- ENVA 2.50
- APGE 2.79
- MACD
- ENVA 1.38
- APGE -0.29
- Stochastic Oscillator
- ENVA 86.29
- APGE 25.18
About ENVA Enova International Inc.
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and the United Kingdom. Consumers apply for credit online, receive a decision almost immediately, and can receive funds within one day. Enova acts as either the lender or a third-party facilitator between borrowers and other lenders. The company earns revenue from interest income, finance charges, and other fees, including fees on the transactions between borrowers and third-party lenders. The majority of revenue comes from the United States. The company realizes similar amounts of revenue from each of its three different products: short-term loans, lines of credit, and installment loans.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.